Tumored
Spago's CEO: “We want to expand cancer treatment with effective radiopharmaceuticals”
2024 has marked a defining chapter for Spago Nanomedical, solidifying its position in radionuclide therapy. By focusing its energy...
Spago Nanomedical's SAB on Tumorad's potential
Recently, Spago Nanomedical announced that the company has...
Spago Nanomedicals CDO on the study application
Spago Nanomedical recently submitted an application to...
Tumor clinical start around the corner for Spago Nanomedical
Encouraged by positive preclinical data with Tumorad, Spago...
Spago Nanomedical reports progress
ACS Omega
Spago Nanomedical publishes positive preclinical data
Preclinical data with Spago Nanomedical's radionuclide concept Tumorad has...
Spago Nanomedical starts phase IIa study in endometriosis
Lund-based Spago Nanomedical recently announced that the company has received...
Spago Nanomedical in hot area
Radionuclide therapies for cancer are a hot area that...
Spago Nanomedical about the autumn news flow
During the second quarter, the Lunda company Spago Nanomedical carried out a...
Spago Nanomedical moves towards the clinic with Tumorad
Shortly before the end of the year, Lund-based Spago Nanomedical announced that...
Spago Nanomedical steps up with capital injection
The Lund company Spago Nanomedical raises capital via a...
Spago Nanomedical towards a clinic with a clear plan
First North-listed Spago Nanomedical's CEO Mats Hansen told...